Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas
Objective This study aims to calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from all in-scope activities involved in phase 1, 2, 3 and 4 clinical trials spanning multiple disease areas.Design The study design involved a retrospective analysis of completed clini...
Saved in:
| Main Authors: | Michael Collins, Thomas Costelloe, Jason Keith LaRoche, Rodrigo Alvarenga, Wouter De Soete, Jeremy Faludi, Kristel Rens, Jason Lanier, Annemie Chiau, Hugh Whetherly |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-02-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/2/e085364.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impacts of informant replacement in two industry‐sponsored Alzheimer's disease clinical trials
by: Mikaela K. Nishida, et al.
Published: (2024-10-01) -
Investigator-initiated versus industry-sponsored trials – visibility and relevance of randomized controlled trials in clinical practice guidelines (IMPACT)
by: Manuel Hecht, et al.
Published: (2025-03-01) -
Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence Approach
by: Leonardo Rojas, et al.
Published: (2025-08-01) -
What is the carbon footprint of academic clinical trials? A study of hotspots in 10 trials
by: Peter Doran, et al.
Published: (2024-10-01) -
Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study
by: Joseph S Ross, et al.
Published: (2023-10-01)